Advanced Life Sciences Holdings, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs in the therapeutic areas of infection, oncology, and respiratory disease. The company's lead product candidate includes Restanza, a once-a-day oral antibiotic for the treatment of respiratory tract infections, including community acquired bacterial pneumonia and biodefense pathogens, such as anthrax, plague, and tularemia. It is also developing ALS-357, a compound for the topical treatment of malignant melanoma; and ALS-886, a therapeutic for the treatment of inflammation-related tissue damage consisting of tissue damage associated with acute respiratory distress syndrome. The company has collaboration agreements with Abbott Laboratories to develop and commercialize cethromycin; University of Illinois to develop, make, use, and sell ALS-357 and related compounds; and Baxter International, Inc. Advanced Life Sciences Holdings, Inc. was founded in 1999 and is headquartered in Woodridge, Illinois.

• Download SqueezeTrigger (TM) Report
• Download FrictionFactor Report
• Download Daily Short Volume Report
• Download Real-Time Short Volume Tool
• Download Failures to Deliver

• No BuyIns.Net Alerts Available for ADLS